Education
About Us
Working with TipRanks
Follow Us
Thermo Fisher Scientific (DE:TN8)
:TN8
TN8 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€350.00 - €590.90
Previous CloseN/A
Volume2.00
Average Volume (3M)324.00
Market Cap
€139.04B
Enterprise ValueN/A
Total Cash (Recent Filing)€5.95B
Total Debt (Recent Filing)$34.19B
Price to Earnings (P/E)23.0
Beta0.62
Next Earnings
Jul 23, 2025EPS Estimate
4.67Last Dividend Ex-Date
Mar 14, 2025Dividend Yield0.39%
Share Statistics
EPS (TTM)4.60
Shares Outstanding377,493,930
10 Day Avg. Volume374
30 Day Avg. Volume324
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio22.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€501.83Price Target Upside37.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Investment And ExpansionPlans to invest US$2bn over the next four years in expanding its US manufacturing and R&D facilities in response to growing customer demand.
Revenue GuidanceManagement maintained its full-year revenue guidance, projecting revenue growth of 1.0% to 3.1% for 2025.
Bears Say
Financial PerformanceTMO lowered core growth assumptions to +1-3% from +3-4% due to incremental headwinds tied to China tariffs and U.S. policy.
Revenue ImpactThermo Fisher Scientific is facing a $400 million top-line headwind from US-to-China sales and a $500 million headwind related to US policy changes.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.12% Insiders
24.12%
Mutual Funds
3.36% Other Institutional Investors
52.77% Public Companies and Individual Investors
TN8 FAQ
What was Thermo Fisher Scientific’s price range in the past 12 months?
Thermo Fisher Scientific lowest stock price was €350.00 and its highest was €590.90 in the past 12 months.
What is Thermo Fisher Scientific’s market cap?
Thermo Fisher Scientific’s market cap is €139.04B.
When is Thermo Fisher Scientific’s upcoming earnings report date?
Thermo Fisher Scientific’s upcoming earnings report date is Jul 23, 2025 which is in 64 days.
How were Thermo Fisher Scientific’s earnings last quarter?
Thermo Fisher Scientific released its earnings results on Apr 23, 2025. The company reported €4.597 earnings per share for the quarter, beating the consensus estimate of €4.554 by €0.044.
Is Thermo Fisher Scientific overvalued?
According to Wall Street analysts Thermo Fisher Scientific’s price is currently Undervalued.
Does Thermo Fisher Scientific pay dividends?
Thermo Fisher Scientific pays a Quarterly dividend of €1.421 which represents an annual dividend yield of 0.39%. See more information on Thermo Fisher Scientific dividends here
What is Thermo Fisher Scientific’s EPS estimate?
Thermo Fisher Scientific’s EPS estimate is 4.67.
How many shares outstanding does Thermo Fisher Scientific have?
Thermo Fisher Scientific has 377,493,930 shares outstanding.
What happened to Thermo Fisher Scientific’s price movement after its last earnings report?
Thermo Fisher Scientific reported an EPS of €4.597 in its last earnings report, beating expectations of €4.554. Following the earnings report the stock price went up 4.668%.
Which hedge fund is a major shareholder of Thermo Fisher Scientific?
Currently, no hedge funds are holding shares in DE:TN8
---
Thermo Fisher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€501.83 (37.34% Upside)
€501.83 (37.34% Upside)
Blogger Sentiment
Bullish
DE:TN8 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.26%
12-Months-Change
Fundamentals
Return on Equity
13.73%
Trailing 12-Months
Asset Growth
2.00%
Trailing 12-Months
Company Description
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
---
TN8 Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial performance and strategic initiatives in innovation and M&A. However, significant challenges were noted due to macroeconomic conditions, US-China tariffs, and pressures in the academic and government markets.Read More>---
TN8 Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
---
TN8 Stock 12 Month Forecast
Average Price Target
€501.83
▲(37.34% Upside)
Technical Analysis
---